Log In
Print
BCIQ
Print
Print this Print this
 

Vimpat, lacosamide

Also known as: formerly harkoseride

  Manage Alerts
Collapse Summary General Information
Company UCB Group
DescriptionAnticonvulsant that selectively enhances slow inactivation of sodium (Na) channels and modulates collapsin response mediator protein-2 (DPYSL2; CRMP-2)
Molecular Target Collapsin response mediator protein-2 (DPYSL2) (CRMP-2)
Mechanism of Action 
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$220.9M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today